Literature DB >> 3008895

Expression of cytolytic functions in HL-60 leukaemic cells after induction of polymorphonuclear leukocyte differentiation.

F Dallegri, A Ballestrero, G Frumento, F Patrone.   

Abstract

Mature polymorphonuclear leukocytes (PMN) are capable of mediating phorbol myristate acetate (PMA)- and antibody (A)-dependent cellular cytotoxicity (DCC) against ox red blood cells (ORBC) by using oxidative means. The purpose of the present study was to investigate the acquirement of these cytotoxic functions during PMN ontogeny, using the promyelocytic HL-60 cell line as a model for PMN differentiation. HL-60 cells were induced to differentiate along the PMN pathway by exposure to dimethyl sulfoxide (DMSO). Uninduced HL-60 cells were found to be completely devoid of PMA-DCC and ADCC activity. DMSO-induced cells progressively acquired the capacity to kill ORBC and to undergo the activation of oxidative metabolic burst when triggered by PMA. Despite approximately 40% of them also were capable of binding IgG-sensitized ORBC, no ADCC activity and respiratory burst activation was observed: this finding indicates that maturing HL-60 cells require a more complete maturation than that induced by DMSO to actually exert ADCC. Together the results suggest that: a. the acquirement of both PMA-DCC and ADCC potential is a post-promyelocytic event; b. the cytotoxicity activating stimuli, PMA and IgG-coated targets, follow different post-receptor transductional pathways to trigger the effector cell lytic systems: only the PMA receptor-linked pathway develops during DMSO-driven differentiation of HL-60 cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3008895     DOI: 10.1007/bf00321084

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  13 in total

1.  Biological defense mechanisms. The production by leukocytes of superoxide, a potential bactericidal agent.

Authors:  B M Babior; R S Kipnes; J T Curnutte
Journal:  J Clin Invest       Date:  1973-03       Impact factor: 14.808

2.  Esterases in human leukocytes.

Authors:  C Y Li; K W Lam; L T Yam
Journal:  J Histochem Cytochem       Date:  1973-01       Impact factor: 2.479

3.  Studies in acute leukemia. I. Antibody-dependent and spontaneous cellular cytotoxicity by leukemic blasts from patients with acute nonlymphoid leukemia.

Authors:  G Fernandes; T Garrett; M Nair; D Straus; R A Good; S Gupta
Journal:  Blood       Date:  1979-09       Impact factor: 22.113

4.  Antibody-dependent cellular cytotoxicity of leukaemic blast cells and neutrophils from patients with acute myelogenous leukaemia.

Authors:  F Dallegri; G Holm; G Gahrton
Journal:  Clin Exp Immunol       Date:  1982-02       Impact factor: 4.330

5.  Extracellular cytolysis by leukaemic blast cells.

Authors:  F Dallegri; F Patrone; G Frumento; A Ballestrero; C Sacchetti
Journal:  Br J Haematol       Date:  1984-01       Impact factor: 6.998

Review 6.  Induction of differentiation of human acute myelogenous leukemia cells: therapeutic implications.

Authors:  H P Koeffler
Journal:  Blood       Date:  1983-10       Impact factor: 22.113

7.  Serum-associated inhibition of neutrophil Fc receptors in cancer patients.

Authors:  F Patrone; F Dallegri; A Gremmo; E Bonvini; P Migliorini; S Cantarella; M Ferrarini; C Sacchetti
Journal:  J Natl Cancer Inst       Date:  1981-10       Impact factor: 13.506

8.  Antibody-dependent haemolytic activity of human leukaemic cells.

Authors:  G Holm; M Björkholm; B Böttiger; H Mellstedt; D Pettersson; C Simonsson-Lindemalm
Journal:  Clin Exp Immunol       Date:  1980-10       Impact factor: 4.330

9.  Ox erythrocyte cytotoxicity by phorbol myristate acetate-activated human neutrophils.

Authors:  F Dallegri; F Patrone; E Bonvini; G Gahrton; G Holm; C Sacchetti
Journal:  Scand J Immunol       Date:  1983-02       Impact factor: 3.487

10.  Antibody-dependent cellular cytotoxicity of leukemic cells from the patients with acute myeloid leukemia to human erythrocytes coated with anti-D antiserum.

Authors:  T Shindo; Y Nakayama; T Akihama; A B Miura
Journal:  Acta Haematol       Date:  1983       Impact factor: 2.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.